Every Form 4 that Evolus, Inc. (EOLS) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow EOLS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full EOLS filings page.
Evolus, Inc. (EOLS) reported that President and Chief Executive Officer David Moatazedi sold 105,108 shares of common stock on September 2, 2026, in an open-market transaction at a weighted average price of $9.04 per share. Following this sale, he directly holds 499,592 shares of Evolus common stock.
Evolus, Inc. officer Rui Avelar reported an open-market sale of 3,119 shares of common stock at a weighted average price of $4.75 per share. According to the filing, these shares were sold under a pre-arranged Rule 10b5-1 trading plan to cover tax withholding obligations from restricted stock unit settlements. Following the sale, Avelar directly holds 427,423 Evolus shares, indicating this was a relatively small, tax-related transaction rather than a large discretionary sale.
Evolus, Inc. director and officer David Moatazedi reported an open-market sale of 13,669 shares of common stock at a weighted average price of $4.7501 per share. According to the filing, the trades were executed under a Rule 10b5-1 trading plan and were required to cover tax withholding obligations from the settlement of restricted stock unit awards. After these transactions, Moatazedi directly holds 604,700 Evolus shares, indicating this was a relatively small, tax-driven adjustment to his overall equity position.
Evolus, Inc. director and officer David Moatazedi reported a mix of equity compensation vesting and related share sales. On March 16, 2026, 67,489 performance restricted stock units (PSUs) vested and settled into the same number of common shares after achievement of 100% of target performance on a 134,977-PSU award granted on February 7, 2024. The remaining 67,488 PSUs from that grant are scheduled to vest on February 7, 2027, subject to continued service.
On March 17, 2026, he sold 116,720 shares of common stock in open-market transactions at a weighted average price of $4.8883 per share. According to the disclosure, these sales were made under a Rule 10b5-1 trading plan and were required to cover tax withholding obligations tied to the vesting and settlement of multiple PSU and restricted stock unit awards. Following these transactions, Moatazedi directly held 618,369 shares of Evolus common stock.
Evolus, Inc. executive Rui Avelar reported a routine mix of equity vesting and tax-related share sales. On March 16, 2026, 8,804 performance restricted stock units vested and converted into common shares at a conversion price of $0.0000 per share, with 8,802 PSUs scheduled to vest on February 7, 2027 subject to continued service. On March 17, 2026, he sold 29,996 common shares at a weighted average price of $4.8883 per share under a Rule 10b5-1 trading plan to cover tax withholding obligations tied to multiple PSU and restricted stock unit awards. Following these transactions, he directly holds 430,542 shares of Evolus common stock.
Parschauer Karah Herdman reported acquisition or exercise transactions in this Form 4 filing.
Evolus, Inc. director Karah Herdman Parschauer reported an equity compensation grant in the form of restricted stock units (RSUs). The filing shows an award of 45,559 shares of common stock at a price of $0.00 per share, bringing her directly owned total to 77,742 shares.
According to the disclosure, these 45,559 RSUs each represent a contingent right to receive one share of Evolus common stock. The RSUs are scheduled to vest in full on the one year anniversary of February 17, 2026, if she remains in continuous service through the vesting date, with potential accelerated vesting in certain change-of-control and other specified events.
Stewart Brady reported acquisition or exercise transactions in this Form 4 filing.
Evolus, Inc. director Stewart Brady reported receiving a grant of 45,559 shares of common stock in the form of restricted stock units (RSUs). The award was priced at $0.00 per share, increasing his directly held common stock (including RSUs) to 134,188 shares after the transaction.
Each RSU represents a contingent right to receive one Evolus common share. The RSUs will vest in full on the one-year anniversary of February 17, 2026, if Brady remains in continuous service through the vesting date, with potential accelerated vesting upon certain changes of control of the company.
Evolus, Inc. Chief Financial Officer Tatjana Mitchell reported equity awards on Form 4. She acquired 121,489 performance restricted stock units, 177,471 stock options, and 121,489 shares of common stock at a grant price of $0.00 per share, all held directly.
The restricted stock units vest in four equal annual installments starting on February 17, 2026, with potential acceleration upon certain terminations or a change in control. The performance-based units can deliver up to 200% of the granted amount based on financial metrics and relative total shareholder return over a three-year period ending December 31, 2028. The stock options also vest in four equal annual installments beginning on February 17, 2026, subject to continued service and similar acceleration conditions.
White Albert G III reported acquisition or exercise transactions in this Form 4 filing.
Evolus, Inc. director Albert G. White III received an equity award of 45,559 shares of common stock in the form of restricted stock units (RSUs) on February 17, 2026. The award was granted at no cash cost per share and is a stock-based compensation grant, not an open-market purchase.
Each RSU represents a contingent right to receive one Evolus common share and will vest in full on “the one year anniversary of February 17, 2026,” if he remains in continuous service, with potential accelerated vesting upon certain changes of control. Following this grant, his reported direct holdings total 95,937 shares of common stock.
MOATAZEDI DAVID reported acquisition or exercise transactions in this Form 4 filing.
Evolus, Inc. director and officer David Moatazedi reported equity awards on February 17, 2026. He was granted 626,424 performance-based restricted stock units, where each unit can deliver up to 200% of a target share amount based on financial metrics and relative total shareholder return over a three-year period ending December 31, 2028. He also received 313,212 time-based restricted stock units and 457,541 stock options, each vesting in four equal annual installments starting on February 17, 2026, subject to continued service and potential acceleration in certain circumstances.
Malik Vikram reported acquisition or exercise transactions in this Form 4 filing.
Evolus, Inc. director Vikram Malik reported an equity award of 45,559 shares of common stock in the form of restricted stock units (RSUs). Each RSU represents the right to receive one share of Evolus common stock for no cash payment.
The RSUs will vest in full on the one year anniversary of February 17, 2026, as long as Malik remains in continuous service, with accelerated vesting possible in certain change-of-control or similar events. After this grant, Malik beneficially owns 321,109 shares of Evolus common stock.
Avelar Rui reported acquisition or exercise transactions in this Form 4 filing.
Evolus, Inc. reported that company officer Rui Avelar received new equity awards on February 17, 2026. Grants included 94,913 performance-based restricted stock units, 94,913 time-based restricted stock units payable in common stock, and stock options for 138,649 shares at no cost on grant.
The time-based RSUs and options vest in four equal annual installments starting February 17, 2026, subject to continued service and possible acceleration in certain circumstances. The performance-based units can deliver up to 200% of the granted PSUs based on financial metrics and relative total shareholder return over a three-year period ending December 31, 2028.
GILL DAVID N reported acquisition or exercise transactions in this Form 4 filing.
Evolus, Inc. director David N. Gill received a grant of 45,559 restricted stock units (RSUs) of common stock. The award was made at no cash cost per share and will vest in full on the one-year anniversary of February 17, 2026, if he remains in continuous service. Following this grant, Gill directly holds 86,887 shares or share-equivalent RSUs.
Evolus, Inc. reported that its Chief Financial Officer was granted both restricted stock units and stock options on 09/08/2025. The CFO received 104,603 RSUs, each convertible into one share on settlement, and a stock option covering 143,403 shares with an exercise price of $7.61 that expires on 09/08/2035. The RSUs vest over four years with one-half vesting on each of the third and fourth anniversaries of the grant date, while the option vests in four annual tranches starting on the first anniversary. Both awards include accelerated vesting in specified termination or change‑of‑control events. Following the grants the reporting person beneficially owns 104,603 shares and has the right to acquire 143,403 additional shares under the option.